Weekly Special Report: Moderna (#MODERNA)

 

THE COMPANY:

• MODERNA'S BUSINESS: Moderna specializes in messenger RNA (mRNA) technology, which enables cells to produce proteins that trigger immune responses or support therapeutic applications. The company focuses on vaccines and treatments for infectious diseases, cancer and rare diseases. Moderna's marketed products include Spikevax and mNEXSPIKE, its COVID-19 vaccines, and mRESVIA, its RSV vaccine. Its portfolio is expanding as the company seeks to diversify beyond COVID-19 vaccines.
• MODERNA'S CANCER VACCINE: In collaboration with Merck, Moderna is developing intismeran autogene, a personalized mRNA-based cancer treatment designed to help the immune system recognize and target tumor cells. Combined with Merck's Keytruda, the treatment showed positive Phase 3 results in high-risk melanoma in August 2026.
• MODERNA'S LATEST PIPELINE: The company's research portfolio includes seasonal influenza and combination flu/COVID vaccines, a norovirus vaccine, treatments for rare diseases, and experimental cancer therapies.

 

MODERNA: EVENTS

• SATURDAY, OCTOBER 24: MODERNA AND MERCK TO PRESENT PHASE 3 DATA FOR PERSONALIZED mRNA CANCER VACCINE. The companies are due to disclose detailed Phase 3 findings for their individualized mRNA-based cancer vaccine, intismeran autogene, administered alongside Keytruda. The presentation at the ESMO Congress in Madrid will provide further evidence on the treatment's potential in patients with melanoma.
• THURSDAY, NOVEMBER 6, PREMARKET (CONFIRMED): Q3 EARNINGS REPORT. The company is expected to print around $887 million in revenue, up around 511% from Q2 of 2026. The company is expected to print a net loss equal to $426 million, down from its net loss in Q2 of 782 million dollars.  
• THURSDAY, NOVEMBER 12: MODERNA ANALYST DAY. Moderna's scheduled Analyst Day could provide updates on its development pipeline, commercial strategy and financial outlook. Investors will look for details on potential growth drivers and the company's progress toward expanding beyond COVID-19 vaccines.

 

MODERNA: NEWS

• FRIDAY, OCTOBER 9: MODERNA REJOINED THE NASDAQ-100 (USA100) INDEX. Moderna joined the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery. Its inclusion could increase demand for Moderna shares from passive funds tracking the index.

 

MODERNA: SKIN CANCER VACCINE MILESTONE ANNOUNCED

• BREAKING (AUGUST 19): MODERNA AND MERCK ANNOUNCED SUCCESSFUL LATE-STAGE TRIAL RESULTS WITH SKIN CANCER VACCINE. Moderna and Merck reported positive Phase 3 results for their personalized mRNA cancer treatment, intismeran, combined with Keytruda. The trial involving 1,137 melanoma patients showed a lower risk of cancer recurrence and spread, with no new safety concerns.
• NEXT PHASE: REGULATORY REVIEW. Regulators at the U.S. Food and Drug Administration (FDA) will examine effectiveness and safety. The companies have not yet announced a specific FDA filing date.
• POSSIBLE APPROVAL: Potentially as early as next year (2027).
• POTENTIAL COMMERCIAL SALES BEGIN: Potentially 2027.

MODERNA: PRICE ACTION AND TECHNICAL ANALYSIS

• STRONG SUPPORT AREA: $200–$170. Moderna’s share price has moved up above $200, first time since January 2023 and it has found support in the $200–$170 area. All that, after rising by around 257% between August 19 and October 12, 2026.
• MODERNA STOCK PRICE HIT AN ALL-TIME HIGH OF $498.28 (August, 2021). Moderna stock price currently trades at $204, and if a full recovery to its previous all-time high occurs, it could see an upside potential of around 144%. However, it could also decline.

GRAPH (Weekly): August 2020 – October 2026

Please note that past performance does not guarantee future results

 

#MODERNA, October 13, 2026
Current Price:   204

 

Example of calculation based on weekly market trend for 1.00 Lot¹

1.  The above calculations are made based on 1.00 lot which is equivalent of 1000 units
2.  Calculations for exchange rate used as of 14:00 (GMT+1) 13/10/2026

 

You can use risk management tools such as Stop-Loss and Take-Profit